REGENXBIO (RGNX) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
REGENXBIO (RGNX) has outperformed Valneva (VALN) over the past year, losing 33.8% versus a loss of 48.4%. Over five years, RGNX leads with a -77.5% price change compared with -79.7% for VALN. Valneva is the larger company by market cap ($539.5 million vs $534.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGNX | VALN |
|---|---|---|
| Share price | $8.09 | $5.69 |
| Market cap | $534.05M | $539.55M |
| 1-day change | +6.52% | -3.07% |
| YTD return | -43.82% | -35.49% |
| 1-year return | -33.80% | -48.41% |
| 5-year return | -77.50% | -79.71% |
| Forward P/E | — | 4.78 |
| EPS (TTM) | $-3.78 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.19 | $12.18 |
| 52-week low | $5.46 | $4.75 |
| Distance from 52-week high | -50.03% | -53.28% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +191.47% | +115.29% |
| Average volume | 1.53M | 78.17K |
| Shares outstanding | 66.01M | 94.82M |
| Employees | 371 | 620 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGNX has outperformed VALN by 14.6 percentage points over the past year.
- The two companies sit in different sectors: REGENXBIO in Healthcare and Valneva in Health Care.
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Healthcare · Biotechnology · 371 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
RGNX vs VALN FAQ
Which is bigger, REGENXBIO or Valneva?
Valneva (VALN) is larger, with a market capitalization of $539.55M compared with $534.05M for REGENXBIO (RGNX).
Which stock has performed better over the past year, RGNX or VALN?
RGNX returned -33.80% over the past 12 months, compared with -48.41% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are REGENXBIO and Valneva in the same industry?
No. REGENXBIO is in the Healthcare sector, while Valneva is in Health Care.